Desmopressin decreases operative blood loss in spinal cord injury patients having flap reconstruction of pelvic pressure sores.

To test the effectiveness of desmopressin in decreasing operative blood loss in major flap reconstructions, 44 hemostatically normal patients with spinal cord injury and pelvic pressure sores participated in a randomized, prospective, double-blind clinical trial. Each patient received a single dose of desmopressin (0.3 micrograms/kg) or saline placebo intravenously at the initiation of a reconstructive surgical procedure. Preoperative and postoperative hemoglobin, hematocrit, von Willebrand factor, and factor VIII determinations and measurement of intraoperative blood loss and transfusions of packed red cells were recorded. Desmopressin-treated patients experienced a smaller decline in hemoglobin and hematocrit levels postoperatively. In those patients requiring major flap reconstructions, the use of desmopressin significantly decreased intraoperative blood loss and subsequent transfusion requirements. The levels of von Willebrand factor and factor VIII tended to be higher, although not significantly so, in subjects receiving desmopressin. No patient experienced an adverse reaction to the drug. We conclude that a single dose of desmopressin, given immediately preoperatively, is safe and effectively decreases blood loss and transfusion requirements in patients undergoing major flap reconstructive surgery.     

Whole blood transfusion in common marmosets: a clinical evaluation

In veterinary medicine, blood transfusion is commonly performed on companion animals. The common marmoset is a small nonhuman primate with increasing popularity as an animal model in biomedical research. Because of its small whole blood volume, the marmoset is at high risk of exsanguination, and blood transfusion is required to care for life-threatening bleeding. However, few clinical evaluations exist on transfusions for marmosets. This study performed whole blood transfusion with cross-matching on nine marmosets and surveyed the therapeutic effects. Recipients included clinical cases with persistent bleeding, anemia, and coma, as well as animals subjected to postoperative bleeding prophylaxis. Donors were selected from healthy marmosets, including littermates. Cross-match assay before transfusion were all negative, and recipients showed no visible signs of transfusion-related adverse reactions. Whole blood transfusions caused hemostasis and successful recovery in bleeding marmosets, including long-term improvement of anemia cases. Our results indicated that blood transfusion is effective for marmosets with severe anemia and persistent hemorrhage from both non-experimental and surgical causes. Furthermore, DNA sequencing for blood-group classification revealed that all subject marmosets were type A, suggesting that the risk of blood type mismatch may be low in this species.     

Nutritional status and postoperative cytokine response in colorectal cancer patients

The present study was designed to investigate the relationship between pre-operative nutritional status and peri-operative regulation of the cytokine network, and to clarify its relation to clinical outcome in colorectal cancer patients. Protein-energy malnutrition was assessed using the creatinine height index. Peripheral venous blood samples were obtained peri-operatively, and the serum concentrations of interleukin (IL-)6, IL-1 receptor antagonist (ra), IL-6 soluble receptor (sR) C-reactive protein (CRP) and the percentage of peripheral neutrophils were determined. Excessive operative blood loss was associated with postoperative morbidity. Pre-operative malnutrition was associated with postoperative mortality when excessive bleeding occurred. Postoperative IL-6 response was exaggerated and postoperative IL-1ra response was suppressed in nutritionally depleted patients. The postoperative serum concentrations of IL-6sR in malnourished patients remained at the lowest levels when excessive bleeding occurred. In these patients, the percentage of peripheral neutrophils remained at high levels even after resolution of the postoperative cytokine storm. A marked activation of the pro-inflammatory cytokine network associated with a decreased antagonistic reaction and an increased consumption of IL-6sR became prominent in malnourished patients when they underwent intense surgical stress. These immunological disturbances may be relevant to neutrophil activation and subsequent clinical outcome.     

Reducing allogenic blood transfusions during pediatric cranial vault surgical procedures: a prospective analysis of blood recycling

Almost all patients who undergo major craniosynostosis corrections receive allogenic blood transfusions. This study of intraoperative blood salvage was undertaken in an attempt to further reduce the need for blood transfusions and to enhance the safety of these complex procedures. This prospective nonrandomized series included 60 consecutive children undergoing major cranial vault remodeling, primarily for treatment of craniosynostosis (single-suture and syndromic). A single craniofacial surgeon performed all operations, using a cell-saver equipped with a 55-cc pediatric bowl. The average age of the patients in this series was 4 years (33 of 60 patients were less than 18 months of age), and the average length of the surgical procedure was 196 minutes. Fifty-three percent were primary procedures and 47 percent were secondary. The mean estimated blood loss was 356 cc (19 cc/kg, or 28.5 percent of the estimated total blood volume). An average of 110 cc of cell-saver blood (range, 5 to 900 cc), or 7.8 percent of the patient's estimated total blood volume (approximately 15 percent, accounting for hemoconcentration of the cell-saver blood), was recycled for transfusion. No statistically significant factors (primary versus secondary procedure, diagnosis, age, or weight) were identified as predictive indicators for the use of this technology. Although 59 of 60 patients received transfusions, only 18 (30 percent) received allogenic blood (average, approximately 140 cc). There were no complications associated with the use of the cell-saver device. Use of the cell-saver during major craniosynostosis repair seemed to be safe and was associated with an extremely low allogenic blood transfusion rate.     

肝内外胆管多发结石肝部分切除术后肝功能衰竭的诊治

目的：探讨肝内外胆管多发结石术后肝功能衰竭的预防、诊断及治疗。方法：我院2011年1 月~2013 年12 月收治肝内外胆 管多发结石行手术治疗患者共126 例,术后发生肝功能衰竭者6 例,均是合并肝叶切除患者。及时准确诊断肝功能衰竭后予抗 炎、护肝、止血、输血、糖皮质激素、抑酸、人血白蛋白、利尿、降血氨、血浆置换及对症支持等治疗。结果：6 例患者出院前复查总胆 红素28.3~ 58.7 mmol/L,谷丙转氨酶16~ 62 U/L,谷草转氨酶12~ 85 U/L,血浆白蛋白32.1~ 37.8 g/L,凝血功能基本正常,腹水消 失,血氨正常,上消化道出血停止。术后12~ 35 d出院,平均18 d。6例患者术后长期随访,目前均存活。结论：肝功能衰竭是肝脏 及胆道术后最为严重的并发症之一,充分的术前准备及评估,术后的及时诊断及治疗,可明显降低其死亡率。     

绿激光膀胱肿瘤汽化术180 例报告

目的:探讨经尿道绿激光膀胱肿瘤汽化术的手术方法、近期疗效及与其它文献方法的比较。方法:采用骶管或硬膜外腔阻滞麻醉,应用美国Laserscope公司生产的非接触式绿激光治疗系统,以30～80W功率对膀胱肿瘤进行汽化。结果:本组汽化时间10～70min,耗能12.23～86.70kJ,出血0～10 ml,术后113例未留置尿管,余67例留置尿管24～96h,膀胱冲洗0～72h,术后住院3～9d,术中均未输血,均未转为开放手术。结论:绿激光膀胱肿瘤汽化术手术安全、操作简单、手术时间短、出血少、痛苦小、留置尿管时间短、康复快,无死角、盲区,可重复性强,是一种理想的微创手术方法。     

Optimal use of blood in trauma patients

Injury is rapidly becoming the leading cause of death worldwide, and uncontrolled hemorrhage is the leading cause of potentially preventable death. In addition to crystalloid and/or colloid based resuscitation, severely injured trauma patients are routinely transfused RBCs, plasma, platelets, and in some centers either cryoprecipitate or fibrinogen concentrates or whole blood. Optimal timing and quantity of these products in the treatment of hypothermic, coagulopathic and acidotic trauma patients is unclear. The immediate availability of these components is important, as most hemorrhagic deaths occur within the first 3–6 h of patient arrival. While there are strongly held opinions and longstanding traditions in their use, there are little data within which to logically guide resuscitation therapy. Many current recommendations are based on euvolemic elective surgery patients and incorporate laboratory data parameters not widely available in the first few minutes after patient arrival. Finally, blood components themselves have evolved over the last 30 years, with great attention paid to product safety and inventory management, yet there are surprisingly limited clinical outcome data describing the long term effects of these changes, or how the components have improved clinical outcomes compared to whole blood therapy. When focused on survival of the rapidly bleeding trauma patient, it is unclear if current component therapy is equivalent to whole blood transfusion. In fact data from the current war in Iraq and Afghanistan suggest otherwise. All of these factors have contributed to the current situation, whereby blood component therapy is highly variable and not driven by long term patient outcomes. This review will address the issues raised above and describe recent trauma patient outcome data utilizing predetermined plasma:platelet:RBC transfusion ratios and an ongoing prospective observational trauma transfusion study.     

Clinical use of blood,blood components and blood products.

The goal of modern transfusion therapy is to provide appropriate replacement therapy with blood components as opposed to whole blood for patients with specific hematologic deficiencies. A prerequisite of component therapy is, therefore, correct identification of the deficiency. Appropriate use of components avoids many of the hazards associated with the use of whole blood, and at the same time makes maximal use of this valuable resource. Blood components separated from whole blood soon after collection and appropriately stored can, in combination, provide all the factors present in fresh whole blood. Red cell concentrates prepared from multiple packs have a hematocrit of approximately 70%. They may be stored for up to 3 weeks at 4 degrees C and are recommended for most situations requiring red cell transfusions. Platelet concentrates, which can be stored for up to 72 hours at 22 degrees C, may be used for thrombocytopenic patients. Fresh frozen plasma, stored plasma, cryoprecipitated factor VIII, factor VIII concentrate and factor IX complex concentrate are available for the proper treatment of patients with hemorrhagic disorders due to coagulation factor deficiencies. Similarly, albumin and immune serum globulin are available for their oncotic and antibody properties respectively. Thus, the availability and appropriate use of the various blood products allows not only optimal transfusion therapy for each patient, but also fuller utilization of national blood resources.     

突发先兆子痫并颅内出血与癫痫1例病例报道并文献复习

目的：探讨突发先兆子痫并颅内出血及癫痫发作行紧急临床治疗的可行性及效果。方法：妊娠孕妇突发先兆子痫并颅内出血及癫痫发作,急诊行剖宫产手术及侧脑室引流术。结果：术后CT扫描显示无血肿,且病理报告表明无恶性细胞异型性及动静脉畸形等疾病。在ICU病房中,3天后患者清醒,给予拔除气管插管处理,5天后患者肝功能及凝血功能恢复正常。结论：对于妊娠突发先兆子痫并颅内出血及癫痫发作行积极对症治疗,可以改善孕妇的生存质量。     

传统开颅手术、显微镜下微创手术治疗基底节区高血压脑出血的临床疗效分析

目的:观察和比较传统开颅手术、显微镜下微创手术治疗基底节区高血压脑出血的临床疗效及安全性。方法:选择2011年10月至2016年1月在我院进行手术治疗的基底节区高血压脑出血患者320例,根据手术方式分为两组,每组160例患者。A组患者接受传统开颅血肿清除术,B组患者接受显微镜下小骨窗血肿清除术,比较两组患者的手术情况、临床疗效、术后生活质量的变化和不良反应的发生情况。结果:B组患者手术时间、ICU时间以及住院时间均较A组显著缩短(P0.05),术中失血量、CSS评分以及术后24 h的血肿量显著低于A组(P0.05),术后1个月临床总有效率显著高于A组(P0.05)。随访6个月期间,B组生活质量显著优于A组(P0.05),术后肺部感染、再次出血的发生率均显著低于A组(P0.05)。结论:显微镜下行小骨窗血肿清除术治疗基底节区高血压脑出血的临床疗效显著优于传统开颅血肿清除术,且创伤较小,可有效缩短手术时间,提高手术安全性。     

The Efficacy and Cost-Effectiveness of Cell Saver Use in Instrumented Posterior Correction and Fusion Surgery for Scoliosis in School-Aged Children and Adolescents

Posterior spinal instrumentation and fusion surgery in school-aged children and adolescents is associated with the potential for massive intraoperative blood loss, which requires significant allogeneic blood transfusion. Until now, the intraoperative use of the cell saver has been extensively adopted; however, its efficacy and cost-effectiveness have not been well established. Therefore, the aim of this study is to determine the efficacy and cost-effectiveness of intraoperative cell saver use. This study was a single-center, retrospective study of 247 school-aged and adolescent patients who underwent posterior spinal instrumentation and fusion surgery between August 2007 and June 2013. A cell saver was used intraoperatively in 67 patients and was not used in 180 patients. Matched case-control pairs were selected using a propensity score to balance potential confounders in baseline characteristics. Allogeneic red blood cell (RBC) and plasma transfusions as well as blood transfusion costs were analyzed. The propensity score matching produced 60 matched pairs. Compared to the control group, the cell saver group had significantly fewer intraoperative allogeneic RBC transfusions (P = 0.012). However, when the combined postoperative and total perioperative periods were evaluated for the use of allogeneic RBC transfusion, no significant differences were observed between the two groups (P = 0.813 and P = 0.101, respectively). With regard to the total cost of perioperative transfusion of all blood products (RBC and plasma), costs for the control group were slightly lower than those of the cell saver group, but this variance did not reach statistical significance (P = 0.095). The use of the cell saver in posterior spinal instrumentation and fusion surgery in school-aged children and adolescents was able to decrease the amount of intraoperative allogeneic RBC transfusion but failed to decrease total perioperative allogeneic RBC transfusion. Moreover, the use of the cell saver was not cost-effective.     

微创颅内血肿清除术对神经细胞损伤因子及血清炎症因子的影响

本研究选取2015年6月至2017年6月我院收治的高血压脑出血患者124例,根据不同的治疗方法分为对照组和观察组。对照组患者采用常规治疗,观察组患者采用常规治疗联合微创颅内血肿清除术治疗,分析微创颅内血肿清除术对脑出血血清铁蛋白(SF)、神经营养因子(NTF)水平以及血清中炎症因子的影响及临床治疗效果。结果表明,治疗前,两组患者出血量、昏迷程度评分比较无统计学差异(p>0.05);治疗后,观察组患者出血量、昏迷程度评分低于对照组(p<0.05)。治疗前,两组患者MMP-9、SF、NTF、GFAP、TNF-α、hs-CRP水平比较无统计学差异(p>0.05);治疗后,观察组患者MMP-9、SF、NTF、GFAP、TNF-α、hs-CRP水平低于对照组(p<0.05)。治疗前,两组患者神经功能评分比较无统计学差异(p>0.05);治疗7 d、14d后,观察组患者神经功能评分低于对照组(p<0.05)。本研究的结果初步说明,微创颅内血肿清除术治疗脑出血可减少患者出血量,降低患者血清炎症因子水平及神经细胞损伤因子的表达水平,改善患者神经功能。     

Influence of perioperative whole blood transfusions on lymphocyte subpopulations in patients with stage II breast cancer

Preliminary reports have suggested an adverse relationship between blood transfusion and survival after surgery in patients with solid tumour. One might postulate that from these studies, perioperative blood transfusions alter host immune defences. We therefore examined the influence of homologous whole blood transfusion on circulating lymphocyte subpopulations in transfused patients compared with non-transfused patients. Fifty-one women with Stage II breast cancer who underwent surgical procedures were studied. Patients were classified into two groups on the basis of whether or not they had received blood transfusion. The lymphocyte subpopulations were analyzed by flow cytometry before cancer surgery and three weeks after the operation. CD3⁺, CD4⁺, CD8⁺, and CD20⁺ cells as the lymphocyte subsets were quantitated using appropriate monoclonal antibodies. No significant differences between pre- and postoperative lymphocyte subset levels were seen in non-transfused patients. However, there was a statistically significant increase in the CD8⁺ cell count; decreasing CD4⁺ cell count and decreased CD3⁺ cells levels were observed in the transfused group (P<0.05). Although these early results of the study suggest that the blood transfusions could be associated with alterations in lymphocyte populations, additional studies are needed to elucidate the possible mechanism of the transfusion-induced immunological modulations.     

高脂血症对直肠癌不同手术方式合并症的影响

目的:探讨高脂血症对直肠癌不同手术方式合并症的影响。方法:回顾分析行开腹或腹腔镜直肠癌根治术治疗的255例患者的临床资料,比较伴或不伴高脂血症患者的围手术期指标,采用卡方检验或t检验进行统计学分析。结果:与非高脂血症组患者相比,高脂血症组术中出血量大(P<0.01),术后恢复进食时间长(P<0.01),术后住院时间增加(P<0.05),拔除引流管时间延长(P<0.01),切口脂肪液化并发症增多(P<0.05)。与开腹组相比,腹腔镜组术中出血量少(P<0.01),手术时间、术后恢复进食时间、术后住院时间、拔除引流管时间均明显缩短(均为P<0.01),切口脂肪液化发生率低(P<0.05)。在腹腔镜手术组,与正常血脂组相比,高脂血症患者术中出血量较大(P<0.01),余指标无明显差异。结论:高脂血症可引起直肠癌手术出血量增加、术后恢复慢、伤口脂肪液化发生率高,腹腔镜手术可加快患者术后恢复。     

The role of Willebrand factor in platelet - blood vessel interaction, including a discussion of resistance to atherosclerosis in pigs with von Willebrand's disease

Von Willebrand pigs have all the manifestations of the severe human disease. The role of Willebrand antigen (VIII R:AG) and ristocetin cofactor (VIII: RWF) was assessed in these pigs by (1) transfusion and (2) "in vitro" bleeding time assay. The skin bleeding time became normal when the level of transfused Willebrand factor (VIII R:AG/RWF) was raised in the plasma above 30 U/dl. After single or repeated transfusions, skin capillary endothelium and platelets were still distinguished from normal by VIII R:AG deficiency. When incisions in excised porcine skin ("in vitro" bleeding time) were perfused with blood and plasma fractions, haemostasis occurred when plasmatic Willebrand factor exceeded 30 U/dl whether the skin or platelets came from normal or from von Willebrand pigs. The platelet plug occluding the skin incision contained VIII R:AG by immunofluorescence. Willebrand factor appears to coat surfaces and to serve as a platelet attachment protein. These bleeder pigs are resistant to atherosclerosis. If platelets are involved in early atherosclerotic lesions, the role of Willebrand factor in platelet - blood vessel interaction may be important.     

Robotic versus Open Radical Cystectomy: An Updated Systematic Review and Meta-Analysis

Objective

To critically review the currently available evidence of studies comparing robot-assisted radical cystectomy (RARC) with open radical cystectomy (ORC).

Methods

A comprehensive review of the literature from Pubmed, Web of Science and Scopus was performed in April 2014. All relevant studies comparing RARC with ORC were included for further screening. A pooled meta-analysis of all comparative studies was performed and publication bias was assessed by a funnel plot.

Results

Nineteen studies were included for the analysis, including a total of 1779 patients (787 patients in the RARC group and 992 patients in the ORC group). Although RARC was associated with longer operative time (p <0.0001), patients in this group might benefit from significantly lower overall perioperative complication rates within 30 days and 90 days (p = 0.005 and 0.0002, respectively), more lymph node yields (p = 0.009), less estimated blood loss (p <0.00001), lower need for perioperative and intraoperative transfusions (p <0.0001 and <0.0001, respectively), and shorter postoperative length of stay (p = 0.0002). There was no difference between two groups regarding positive surgical margin rates (p = 0.19).

Conclusions

RARC appears to be an efficient alternative to ORC with advantages of less perioperative complications, more lymph node yields, less estimated blood loss, lower need for transfusions, and shorter postoperative length of stay. Further studies should be performed to compare the long-term oncologic outcomes between RARC and ORC.     

Risk Factors for Blood Transfusions in Primary Anatomic and Reverse Total Shoulder Arthroplasty for Osteoarthritis

BackgroundThe purpose of this study was to determine risk factors for blood transfusion in primary anatomic and reverse total shoulder arthroplasty (TSA) performed for osteoarthritis.MethodsPatients who underwent anatomic or reverse TSA for a diagnosis of primary osteoarthritis were identified in a national surgical database from 2005 to 2018 by utilizing both CPT and ICD-9/ICD-10 codes. Univariate analysis was performed on the two transfused versus non-transfused cohorts to compare for differences in comorbidities and demographics. Independent risk factors for perioperative blood transfusions were identified via multivariate regression models.Results305 transfused and 18,124 nontransfused patients were identified. Female sex (p<0.001), age >85 years (p=0.001), insulin-dependent diabetes mellitus (p=0.001), dialysis dependence (p=0.001), acute renal failure (p=0.012), hematologic disorders (p=0.010), disseminated cancer (p<0.001), ASA ≥ 3 (p<0.001), and functional dependence (p=0.001) were shown to be independent risk factors for blood transfusions on multivariate logistic regression analysis.ConclusionSeveral independent risk factors for blood transfusion following anatomic/reverse TSA for osteoarthritis were identified. Awareness of these risk factors can help surgeons and perioperative care teams to both identify and optimize high-risk patients to decrease both transfusion requirements and its associated complications in this patient population. Level of Evidence: III     

Dextran and intermittent pneumatic compression in prevention of postoperative deep vein thrombosis: multiunit trial.

Seven general surgical units co-operated in a clinical trial of dextran 70 and pneumatic calf compression alone and in combination in the preventing of 125I-fibrinogen-detectable deep vein thrombosis in 305 patients. Both dextran regimens were significantly more effective than pneumatic compression alone. Pulmonary embolism was diagnosed in 14 patients, but there was no significant difference in incidence among the three treatment groups. In patients receiving dextran there was no greater median operative blood loss but there was a significantly greater incidence of postoperative bleeding complications.     

Correlation of blood rheology with vascular resistance in critically ill patients.

Blood rheologic measurements together with peripheral resistance determinations in vivo were made in 27 critically ill patients. Eighteen of these patients (group I) suffered from violent trauma or operative injury and the other 9 (group II) were patients with generalized sepsis. As a result of fluid therapy all patients underwent hemodilution, resulting in a decrease in blood viscosity. This drop in blood viscosity was counteracted to some extent by an increased plasma viscosity due to elevated fibrinogen levels and a decreased red cell deformability associated with massive transfusions of stored blood. The correlation of vivo hemodynamics with blood rheological data made it possible to separate the relative roles of vascular dimensions and blood viscosity in affecting the total peripheral resistance. This approach permitted us to distinguish varying degrees of vasoconstriction in nonseptic patients in low flow states (group I) and varying degrees of vasodilation in septic patients (group II). This type of analysis serves to elucidate the pathophysiology of hemodynamic alterations in disease and provides a rational basis for devising an effective therapeutic program.     

Efficacy and Safety of Using Antifibrinolytic Agents in Spine Surgery: a Meta-Analysis

Purpose

Spine surgery, particularly reconstructive surgery, can be associated with significant blood loss, and blood transfusion. Antifibrinolytic agents are used routinely to reduce bleeding in cardiac, orthopaedic, and hepatic surgery. The purpose of this study was to assess the efficacy and safety of using antifibrinolytic agents in reducing blood loss and blood transfusions in spine surgery.

Methods

A systematic search of all related studies written in English published by October 2012 was conducted using the MEDLINE, EMBASE and the Cochrane Library databases. Randomized controlled trials that reported the drug dosage, total blood loss, blood transfusion and incidence of deep vein thrombosis as the primary outcome were included.

Results

Nine studies involving 482 patients were identified. Patients receiving antifibrinolytic agents had reduced blood loss (WMD =-288.8, 95 % CI – 46.49, - 110.19; P = 0.002), reduced blood transfusion (WMD =-242.7, 95 % CI – 422.57, - 62.95; P = 0.008), reduced blood transfusion rate (RR 0.73, 95% CI 0.58, 0.93; p = 0.010) and no increase (RR 0.25, 95 % CI 0.03, 2.22; P = 0.21) in the risk of deep vein thrombosis. Conclusions: We conclude that antifibrinolytic agents significantly decrease blood loss, blood transfusion, and there is no increase in the risk of deep vein thrombosisfor transfusion requirements in spine surgery.